Novo Nordisk Shares Dive After Heart Medicine Fails Trial

3-line summary

• Novo Nordisk shares dove after the experimental medicine ziltivekimab didn't translate into a statistically meaningful reduction in major cardiovascular adverse events, the company said Friday.

This summary is our own processing of the source article; see the source link below for full context.